Marty Duvall, Oncopeptides CEO
October 22, 2021 10:44 AM EDT
Pharma
FDA+

On­copep­tides stock craters as it pulls can­cer drug Pepax­to from the mar­ket

Zachary Brennan

Senior Editor

Shares of On­copep­tides crashed more than 70% in ear­ly Fri­day trad­ing af­ter the com­pa­ny said it’s pulling its mul­ti­ple myelo­ma drug Pepax­to (mel­pha­lan flufe­namide) from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Trump 2.0 blog: Way­back Ma­chine is in­suf­fi­cient for US health da­ta, judge says

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

Bio­haven lands pri­or­i­ty re­view on sec­ond-chance ap­pli­ca­tion for neu­rode­gen­er­a­tive drug

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times